profit from every $100 of sales.
$0$100
Guardant Health
$151.70-2.04% today
+61.2% in 1 year
1-year low $78.601-year high $187.22
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Guardant Health sold, what it kept, and what it did with the cash.
Sales went from $450 million in 2022 to $982 million in 2025, with -$416 million of profit last year.
SalesProfit
Guardant Health vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Guardant Health | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Exact Sciences | No profit yet |
AI analysis
An AI analyst reads Guardant Health's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 287 | 374 | 450 | 564 | 739 | 982 | |
| – | – | 293 | 337 | 449 | 633 | |
| -255 | -411 | -544 | -565 | -444 | -437 | |
| -225 | -360 | -615 | -433 | -390 | -374 | |
| -254 | -385 | -655 | -479 | -436 | -416 | |
| -2.60 | -4.00 | -6.41 | -4.28 | -3.56 | -3.32 | |
| – | – | 65.2% | 59.7% | 60.8% | 64.5% | |
| -88.9% | -110.0% | -121.1% | -100.1% | -60.0% | -44.5% | |
| -88.5% | -103.0% | -145.6% | -85.0% | -59.0% | -42.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 2,272 | 2,204 | 1,610 | 1,786 | 1,486 | 2,014 |
| Cash | 833 | 492 | 142 | 1,134 | 526 | 378 |
| Total debt | – | – | 1,369 | 1,354 | 1,336 | 1,710 |
| Total liabilities | 916 | 1,559 | 1,550 | 1,628 | 1,625 | 2,113 |
| 1,298 | 645 | 60 | 159 | -140 | -99 | |
| 98 | 101 | 102 | 112 | 123 | 125 | |
| -14.7% | -46.8% | -36.0% | -24.9% | -28.6% | -20.3% | |
| -19.5% | -59.7% | -1,087.7% | -302.1% | 312.5% | 419.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -104 | -209 | -309 | -325 | -240 | -185 | |
| 36 | 75 | 77 | 20 | 35 | 48 | |
| -140 | -284 | -387 | -345 | -275 | -233 | |
| Dividends paid | – | – | – | – | – | – |
| 0 | – | – | 0 | 0 | 45 | |
| 144 | 151 | 95 | 91 | 140 | 166 |
Valuation
- –
- –
- –
- -86.9×
- 20.9×
- –
- –
- -1.1%
- -2.0%
- 0.0%
Profitability
- 64.5%
- -44.5%
- -42.4%
- -36.2%
- -27.5%
- -32.1%
- 184.3%
- -22.6%
- -27.6%
- 33.9%
Growth
- +27.9%
- –
- +15.2%
- –
- +5.5%
Financial health
- –
- -9.26
- 87.5%
- -100.5×
- 4.68
- 4.39
- 0.56
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 14%of 952
Bottom 7%of 883
Top 19%of 888
Bottom 32%of 987
What analysts expect
- Average price target
- $133.14
- Range
- $110.00 – $175.00
- 9 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.85 | -0.47 | −80.9% |
| Feb 19, 2026 | -0.90 | -0.77 | −17.4% |
| Oct 29, 2025 | -0.39 | -0.48 | +18.7% |
| Jul 30, 2025 | -0.44 | -0.52 | +15.4% |
| Apr 30, 2025 | -0.49 | -0.61 | +19.7% |
| Feb 20, 2025 | -0.62 | -0.75 | +17.3% |
| Nov 6, 2024 | -0.45 | -0.55 | +18.2% |
| Aug 7, 2024 | -0.48 | -0.57 | +15.8% |
News
Guardant Health loses challenge regarding DNA sequencing patentSeeking Alpha · Oct 15, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
43No pass
Philip Fisher
42No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
32No pass
Questions about Guardant Health
Is Guardant Health a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Guardant Health AI analysis
What does Guardant Health do?
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. It is in Medical - Diagnostics & Research, based in Palo Alto, CA, United States, with 2,490 employees.
Does Guardant Health pay a dividend?
No. Guardant Health does not pay a dividend at the moment; in 2025 it returned $45.0 million to shareholders by buying back its own shares.
Is Guardant Health stock halal?
Yes. Guardant Health passes our halal screen: its business is permitted and its debt is 8% of its market value, under the 30% limit. How we check
How has Guardant Health stock done over the past year?
Up 61.2% over the past twelve months, to $151.70. It traded between $78.60 and $187.22 and is 19.0% below its high.
Who are Guardant Health's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Exact Sciences. The peers table on this page compares their profit, growth and price with Guardant Health's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.